Compare Stocks: UPB, MLTX, RIGL, and GLUE

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GLUE Monte Rosa Therapeutics	$9.89 -6.0%	$13.32	$8.94 ▼ $25.77	$897.50M	1.37	1.43 million shs	2.71 million shs
MLTX MoonLake Immunotherapeutics	$10.41 -2.5%	$13.98	$8.80 ▼ $23.29	$908.94M	1.08	1.99 million shs	2.41 million shs
RIGL Rigel Pharmaceuticals	$47.14 -3.4%	$46.11	$24.95 ▼ $52.24	$903.09M	1.19	251,551 shs	133,998 shs
UPB Upstream Bio	$3.55 -14.9%	$5.96	$3.52 ▼ $33.68	$228.40M	1.38	832,058 shs	1.04 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GLUE Monte Rosa Therapeutics	-5.99%	+0.20%	-29.71%	-57.75%	-4.90%
MLTX MoonLake Immunotherapeutics	-2.53%	-4.93%	-16.79%	-47.85%	-2.35%
RIGL Rigel Pharmaceuticals	-3.42%	+2.23%	-0.21%	+14.47%	+75.70%
UPB Upstream Bio	-14.87%	-22.66%	-38.05%	-51.17%	-82.32%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GLUE Monte Rosa Therapeutics	$9.89 -6.0%	$13.32	$8.94 ▼ $25.77	$897.50M	1.37	1.43 million shs	2.71 million shs
MLTX MoonLake Immunotherapeutics	$10.41 -2.5%	$13.98	$8.80 ▼ $23.29	$908.94M	1.08	1.99 million shs	2.41 million shs
RIGL Rigel Pharmaceuticals	$47.14 -3.4%	$46.11	$24.95 ▼ $52.24	$903.09M	1.19	251,551 shs	133,998 shs
UPB Upstream Bio	$3.55 -14.9%	$5.96	$3.52 ▼ $33.68	$228.40M	1.38	832,058 shs	1.04 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GLUE Monte Rosa Therapeutics	-5.99%	+0.20%	-29.71%	-57.75%	-4.90%
MLTX MoonLake Immunotherapeutics	-2.53%	-4.93%	-16.79%	-47.85%	-2.35%
RIGL Rigel Pharmaceuticals	-3.42%	+2.23%	-0.21%	+14.47%	+75.70%
UPB Upstream Bio	-14.87%	-22.66%	-38.05%	-51.17%	-82.32%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GLUE Monte Rosa Therapeutics	2.83	Moderate Buy	$26.67	169.63% Upside
MLTX MoonLake Immunotherapeutics	2.43	Hold	$28.50	173.78% Upside
RIGL Rigel Pharmaceuticals	2.57	Moderate Buy	$59.00	25.16% Upside
UPB Upstream Bio	2.43	Hold	$29.67	735.68% Upside

Current Analyst Ratings Breakdown

Latest UPB, MLTX, RIGL, and GLUE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/11/2026	GLUE Monte Rosa Therapeutics	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$17.00 ➝ $19.00
10/8/2026	RIGL Rigel Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Buy (B-) ➝ Buy (B)
10/5/2026	GLUE Monte Rosa Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$25.00
10/5/2026	GLUE Monte Rosa Therapeutics	Benchmark Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
10/5/2026	MLTX MoonLake Immunotherapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$50.00
10/1/2026	GLUE Monte Rosa Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$25.00
10/1/2026	GLUE Monte Rosa Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$25.00
9/16/2026	MLTX MoonLake Immunotherapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Overweight
9/9/2026	RIGL Rigel Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold (C+) ➝ Buy (B-)
9/9/2026	GLUE Monte Rosa Therapeutics	Wedbush Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform	$27.00
9/2/2026	UPB Upstream Bio	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$36.00

(Data available from 10/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GLUE Monte Rosa Therapeutics	$123.67M	6.82	N/A	N/A	$3.58 per share	2.76
MLTX MoonLake Immunotherapeutics	N/A	N/A	N/A	N/A	$4.27 per share	N/A
RIGL Rigel Pharmaceuticals	$294.28M	2.96	$6.51 per share	7.24	$21.57 per share	2.19
UPB Upstream Bio	$2.85M	68.22	N/A	N/A	$6.29 per share	0.56

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GLUE Monte Rosa Therapeutics	-$38.63M	-$1.76	N/A	N/A	N/A	-560.85%	-43.31%	-27.59%	11/5/2026 (Estimated)
MLTX MoonLake Immunotherapeutics	-$227.32M	-$3.84	N/A	N/A	N/A	N/A	-82.53%	-58.17%	11/4/2026 (Estimated)
RIGL Rigel Pharmaceuticals	$367.02M	$16.32	2.89	10.91	N/A	116.30%	22.95%	17.19%	11/3/2026 (Estimated)
UPB Upstream Bio	-$143.44M	-$2.90	N/A	N/A	N/A	-4,955.67%	-48.40%	-46.57%	11/4/2026 (Estimated)

Latest UPB, MLTX, RIGL, and GLUE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2026	Q3 2026	GLUE Monte Rosa Therapeutics	-$0.2396	N/A	N/A	N/A	$33.87 million	N/A
11/4/2026	Q3 2026	MLTX MoonLake Immunotherapeutics	-$0.77	N/A	N/A	N/A	N/A	N/A
11/4/2026	Q3 2026	UPB Upstream Bio	-$0.7286	N/A	N/A	N/A	$0.52 million	N/A
11/3/2026	Q3 2026	RIGL Rigel Pharmaceuticals	$0.9210	N/A	N/A	N/A	$80.10 million	N/A
8/11/2026	Q2 2026	UPB Upstream Bio	-$0.7444	-$0.73	+$0.0144	-$0.73	$0.56 million	$0.77 million
8/10/2026	Q2 2026	MLTX MoonLake Immunotherapeutics	-$0.9086	-$0.84	+$0.0686	-$0.84	N/A	N/A
8/6/2026	Q2 2026	GLUE Monte Rosa Therapeutics	-$0.3805	-$0.43	-$0.0495	-$0.43	$12.91 million	$8.97 million
8/4/2026	Q2 2026	RIGL Rigel Pharmaceuticals	$0.0877	$0.88	+$0.7923	$0.88	$55.28 million	$78.70 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
GLUE Monte Rosa Therapeutics	N/A	N/A	N/A	N/A	N/A
MLTX MoonLake Immunotherapeutics	N/A	N/A	N/A	N/A	N/A
RIGL Rigel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
UPB Upstream Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GLUE Monte Rosa Therapeutics	N/A	10.58	10.58
MLTX MoonLake Immunotherapeutics	0.23	12.56	12.56
RIGL Rigel Pharmaceuticals	N/A	1.94	1.79
UPB Upstream Bio	N/A	27.99	27.99

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GLUE Monte Rosa Therapeutics	79.96%
MLTX MoonLake Immunotherapeutics	93.85%
RIGL Rigel Pharmaceuticals	66.23%
UPB Upstream Bio	N/A

Insider Ownership

Company	Insider Ownership
GLUE Monte Rosa Therapeutics	6.40%
MLTX MoonLake Immunotherapeutics	10.40%
RIGL Rigel Pharmaceuticals	10.47%
UPB Upstream Bio	16.46%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GLUE Monte Rosa Therapeutics	173	85.31 million	79.85 million	Optionable
MLTX MoonLake Immunotherapeutics	130	85.11 million	76.26 million	Optionable
RIGL Rigel Pharmaceuticals	174	18.50 million	16.57 million	Optionable
UPB Upstream Bio	75	54.77 million	45.76 million	N/A

UPB, MLTX, RIGL, and GLUE Headlines

Recent News About These Companies

Upstream Bio, Inc. (NASDAQ:UPB) Stock Rated "Hold" by Wall Street Brokerages

4 hours ago | marketbeat.com

391,762 Shares in Upstream Bio, Inc. $UPB Purchased by Bank of America Corp DE

October 1, 2026 | marketbeat.com

Upstream Bio, Inc. (NASDAQ:UPB) Receives Average Rating of "Hold" from Analysts

September 19, 2026 | marketbeat.com

Hsbc Holdings PLC Sells 629,533 Shares of Upstream Bio, Inc. $UPB

September 18, 2026 | marketbeat.com

Squarepoint Ops LLC Buys 246,278 Shares of Upstream Bio, Inc. $UPB

September 15, 2026 | marketbeat.com

Upstream Bio Reports Phase 2 VALIANT Trial Results Showing Verekitug Reduced Severe Asthma Exacerbations by 56% with Quarterly Dosing

September 8, 2026 | quiverquant.comQ

Upstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026

September 8, 2026 | globenewswire.com

Analysts Are Bullish on These NA Stocks: Upstream Bio, Inc. (UPB), Fervo Energy Company Class A (FRVO)

September 2, 2026 | theglobeandmail.com

Upstream Bio on Track to Begin Two Phase 3 Verekitug Trials in Q1 2027

September 1, 2026 | finance.yahoo.com

Upstream Bio Outlines Phase 3 Plans for Verekitug

September 1, 2026 | tipranks.com

Upstream Bio Announces Pivotal Phase 3 Development Plans for Verekitug in Both Severe Asthma and CRSwNP

September 1, 2026 | globenewswire.com

Upstream Bio Inc (UPB)

August 16, 2026 | investing.com

Upstream Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Progress

August 11, 2026 | markets.businessinsider.com

Upstream Bio, Inc. (UPB) Reports Q2 Loss, Tops Revenue Estimates

August 11, 2026 | zacks.com

Upstream Bio, Inc. (UPB) Upgraded to Buy: What Does It Mean for the Stock?

July 14, 2026 | zacks.com

Is Upstream Bio, Inc. (UPB) a Rising Biotech Opportunity After New Analyst Coverage?

June 25, 2026 | insidermonkey.com

10 small-cap U.S. healthcare stocks with the weakest momentum grades

June 24, 2026 | seekingalpha.com

Is Upstream Bio, Inc. (UPB) the Best Low Priced Stocks to Get Rich in 2026?

June 23, 2026 | insidermonkey.com

Upstream Bio Initiates a Phase 2 Clinical Trial of Verekitug (UPB-101) in Severe Asthma and Doses First Patients

June 19, 2026 | businesswire.com

Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the ...

June 14, 2026 | markets.businessinsider.com

Upstream Bio Reports Positive Phase 2 Results for Verekitug in Chronic Rhinosinusitis with Nasal Polyps, Achieving Clinically Meaningful Improvements in Key Symptoms

June 14, 2026 | quiverquant.comQ

New MarketBeat Followers Over Time

Media Sentiment Over Time

UPB, MLTX, RIGL, and GLUE Company Descriptions

Monte Rosa Therapeutics NASDAQ:GLUE

$9.89 -0.63 (-5.99%)

Closing price 10/13/2026 04:00 PM Eastern

Extended Trading

$9.94 +0.04 (+0.46%)

As of 08:26 AM Eastern

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

MoonLake Immunotherapeutics NASDAQ:MLTX

$10.41 -0.27 (-2.53%)

Closing price 10/13/2026 04:00 PM Eastern

Extended Trading

$10.47 +0.06 (+0.57%)

As of 08:25 AM Eastern

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

Rigel Pharmaceuticals NASDAQ:RIGL

$47.14 -1.67 (-3.42%)

Closing price 10/13/2026 04:00 PM Eastern

Extended Trading

$47.20 +0.06 (+0.13%)

As of 07:44 AM Eastern

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.

Upstream Bio NASDAQ:UPB

$3.55 -0.62 (-14.87%)

Closing price 10/13/2026 04:00 PM Eastern

Extended Trading

$3.62 +0.08 (+2.11%)

As of 08:20 AM Eastern

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest UPB, MLTX, RIGL, and GLUE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest UPB, MLTX, RIGL, and GLUE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

UPB, MLTX, RIGL, and GLUE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

UPB, MLTX, RIGL, and GLUE Company Descriptions

Monte Rosa Therapeutics NASDAQ:GLUE

MoonLake Immunotherapeutics NASDAQ:MLTX

Rigel Pharmaceuticals NASDAQ:RIGL

Upstream Bio NASDAQ:UPB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest UPB, MLTX, RIGL, and GLUE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest UPB, MLTX, RIGL, and GLUE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

UPB, MLTX, RIGL, and GLUE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

UPB, MLTX, RIGL, and GLUE Company Descriptions

Monte Rosa Therapeutics NASDAQ:GLUE

MoonLake Immunotherapeutics NASDAQ:MLTX

Rigel Pharmaceuticals NASDAQ:RIGL

Upstream Bio NASDAQ:UPB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools